

Susanne Malander

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4339293/susanne-malander-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20
papers

424
citations

9
h-index

20
g-index

20
ext. papers

537
ext. citations

5.6
avg, IF

3
L-index

#	Paper	IF	Citations
20	The role of computed tomography in the assessment of tumour extent and the risk of residual disease after upfront surgery in advanced ovarian cancer (AOC).. <i>Archives of Gynecology and Obstetrics</i> , 2022 , 1	2.5	1
19	Prognostic Value of Peritoneal Cancer Index After Complete Cytoreductive Surgery in Advanced Ovarian Cancer.. <i>Anticancer Research</i> , 2022 , 42, 2541-2551	2.3	0
18	Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960-2014: A population-based cohort study. <i>BMC Cancer</i> , 2021 , 21, 465	4.8	0
17	MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer. <i>Genes</i> , 2021 , 12,	4.2	1
16	PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 477, 83-91	5.1	23
15	A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. <i>PLoS ONE</i> , 2020 , 15, e0240418	3.7	4
14	High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 159, 860-868	4.9	3
13	SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery. <i>Molecular and Cellular Oncology</i> , 2020 , 7, 1805094	1.2	3
12	Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOV2/ENGOT-ov24): a randomised, phase 2, superiority trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1409-1419	21.7	105
11	Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study. <i>Acta Oncologica</i> , 2019 , 58, 320-325	3.2	
10	A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer. <i>Molecular and Cellular Proteomics</i> , 2019 , 18, 1836-1850	7.6	24
9	Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method. <i>Scientific Reports</i> , 2019 , 9, 15506	4.9	5
8	Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1117-1125	21.7	65
7	Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS. <i>Cell Reports</i> , 2018 , 23, 2819-2831.e5	10.6	26
6	Involvement of Chromatin Remodeling Genes and the Rho GTPases and in Ovarian Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2017 , 7, 109	5.3	16
5	Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival. <i>Translational Oncology</i> , 2015 , 8, 424-433	4.9	23
4	Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5556-5556	2.2	2

3	Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes. <i>PLoS ONE</i> , 2014 , 9, e107643	3.7	11
2	The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. <i>Gynecologic Oncology</i> , 2006 , 101, 238-43	4.9	112
1	Ovarian tumor frozen section, a multidisciplinary affair. <i>Acta Oncologica</i> , 1-8	3.2	0